financetom
Business
financetom
/
Business
/
Indraprastha Gas-Genesis JV to set up smart meter plant at Rs 110 crore
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Indraprastha Gas-Genesis JV to set up smart meter plant at Rs 110 crore
Jul 17, 2023 9:25 AM

Indraprastha Gas Ltd (IGL), the firm that retails CNG and piped cooking gas in the national capital and other cities, on Monday, July 17, said the company has set up a joint venture with Genesis Gas Solutions Private Ltd with a capex of Rs 110 crore.

Share Market Live

NSE

The joint venture agreement is to set up an integrated smart meter manufacturing plant, the company said in an exchange filing.

Initially, the smart meter manufacturing plant would have an installed capacity to manufacture one million meters annually and is planned to be operational by April 2024.

Further, the joint venture between IGL and Genesis will have equity participation from both the partners in the ratio of 51:49 respectively, the company said.

Indraprastha Gas reported an 8 percent year-on-year decline in consolidated net profit at Rs 397.5 crore for the fourth quarter that ended March 31, 2023. In the corresponding quarter last year, the company posted a net profit of Rs 431 crore.

In the March quarter, total revenue stood at Rs 4,061.63 crore during the period under review, up 52 percent against Rs 2,649.77 crore in the corresponding period of the preceding fiscal.

At the operating level, EBITDA jumped 8.8 percent to Rs 466.3 crore in the fourth quarter of this fiscal over Rs 428.5 crore in the previous quarter.

The EBITDA margin stood at 12.7 percent in the reporting quarter compared to 11.5 percent in the previous quarter. EBITDA is earnings before interest, tax, depreciation, and amortisation.

Shares of Indraprastha Gas Ltd ended at Rs 489.10, up by Rs 1.20, or 0.25 percent on the BSE.

(Edited by : Shoma Bhattacharjee)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
GoldHaven Says Copecal Gold Project in Brazil Holds 'Strong Potential' for Gold Mineralization
GoldHaven Says Copecal Gold Project in Brazil Holds 'Strong Potential' for Gold Mineralization
Feb 10, 2025
08:16 AM EST, 02/10/2025 (MT Newswires) -- GoldHaven Resources ( GHVNF ) on Monday said its 100%-owned Copecal Gold Project in Brazil holds strong potential for gold mineralization as it has a solid foundation of historic exploration data, favorable geological setting, and a systematic exploration strategy. Exploration work conducted by AngloGold Ashanti from 2010 to 2016 had uncovered multiple gold-bearing...
Hain Celestial Explores Strategic Options for Personal Care Business
Hain Celestial Explores Strategic Options for Personal Care Business
Feb 10, 2025
08:18 AM EST, 02/10/2025 (MT Newswires) -- Hain Celestial Group ( HAIN ) said Monday it is exploring strategic options for its personal care business as it shifts focus to its better-for-you food and beverages portfolio. The company reported a 38% year-over-year decline in organic net sales for its personal care business for its fiscal Q2 ended Dec. 31. HAIN...
BRIEF-NXP Agrees To Acquire Edge AI Pioneer Kinara
BRIEF-NXP Agrees To Acquire Edge AI Pioneer Kinara
Feb 10, 2025
Feb 10 (Reuters) - NXP Semiconductors ( NXPI ): * NXP AGREES TO ACQUIRE EDGE AI PIONEER KINARA TO REDEFINE THE INTELLIGENT EDGE * NXP SEMICONDUCTORS NV ( NXPI ) - DEAL VALUED AT $307 MILLION, EXPECTED TO CLOSE IN H1 2025 Source text: Further company coverage: ...
Satellos Bioscience Completes Enrollment of All Dose Cohorts for Phase 1 SAT-3247 Trial
Satellos Bioscience Completes Enrollment of All Dose Cohorts for Phase 1 SAT-3247 Trial
Feb 10, 2025
08:17 AM EST, 02/10/2025 (MT Newswires) -- Satellos Bioscience ( MSCLF ) on Monday said it has completed enrollment of all four multiple-ascending dose cohorts for the Phase 1 clinical trial of SAT-3247 in healthy volunteers. SAT-3247 is a small molecule drug being developed by Satellos to regenerate skeletal muscle which is lost in Duchenne muscular dystrophy (DMD) and other...
Copyright 2023-2026 - www.financetom.com All Rights Reserved